

Curriculum Vitae

JOHN K. DEXTER, M.D., FACP

BUSINESS ADDRESS

Headache Care Center/Clinvest
3805 S. Kansas Expressway
Springfield, MO 65807
Phone: (417)890-7888 • Fax: (417) 890-8827
kdexter@mac.com

EDUCATION

Residency:

Internal Medicine Residency
University of Missouri
Columbia, Missouri
1976-1979

Medical School:

University of Missouri
Columbia, Missouri
1972-1976

USAF

Electronics/Computers
1969-1972

Graduate Studies:

Graduate Studies Human Anatomy
Kansas University Medical Center
Kansas City, MO
1968-1969

College:

Baker University
Bachelor of Science in Chemistry and Math
Baldwin City, Kansas
1964-1968

MEDICAL LICENSE

Missouri (R8794)

PROFESSIONAL EMPLOYMENT

2003-Present

Headache Care Center, Division of Banyan Group, Inc.
Springfield, MO
Medical Director
Headache Specialist
Internal Medicine Physician
Clinvest, Division of Banyan Group, Inc.
Research Investigator

2001-2003

Monroe Clinic
Monroe, WI
Division Chairman for Primary Care, 2002-2003
Managed medical staff credentialing and peer review
Served on Medical Executive Committee

1990-2001

Springfield Clinic Internal Medicine, St. Johns Health System
Springfield, Missouri
Served as Chairman of Internal Medicine, St. Johns Health System
Chief of Medicine, St. Johns Health System
Chairman of Internal Medicine, St. Johns Clinics and Physicians
Served on Executive Committee
Director of Headache Clinic
Medical consulting editor for Healthy Choice On-Line Magazine,
Medical Director of New Images for Weight Loss and Behavior Modification
Managed medical staff credentialing and peer review for St. Johns Health System.

1979-1990

Springfield Clinic Internal Medicine, Professional Corporation
Springfield, Missouri
Served as President from 1988-1990

PROFESSIONAL SOCIETIES

American Medical Association
Missouri State Medical Society
Greene County Medical Society
American College of Physicians
American Headache Society
National Headache Foundation

SPECIALTY CERTIFICATION

Diplomat American Board of Internal Medicine, 1979
Fellowship American College of Physicians, 2001
National Board for Certification in Headache Management, 2005
Certification for Headache Medicine, United Council for Neurologic Subspecialties, 2007

ARTICLES

Cady RK, Farmer KU, Dexter JK and Schreiber CP. Co-sensitization of Pain and Psychiatric Comorbidity in Chronic Daily Headache. *Current Pain and Headache Reports* 2005, 9:47-52.

RESEARCH STUDIES

Clinvest, Inc. Investigator Initiated Studies

Allergan	Efficacy and Satisfaction with Use of Botulinum Toxin Type A (BOTOX) as Migraine Preventive Treatment in Patients Who Have Failed with a Prophylactic Medication Due To Compliance Issues
Matrix	Human Clinical Investigation of Homeopathic Drug for Migraine Headache
Merck	Cognitive and Economic Impact of Migraine Treatment in the Workplace with Rizatriptan vs. Placebo: Effects of Early vs. Delayed intervention

Abbott Laboratories

M03-648	Divalproex Sodium Extended-Release Tablets for Migraine Prophylaxis in Adolescents: An Open-Label, Long-Term Safety Study
M02-488	The Safety and Efficacy of Divalproex Sodium Extended-Release Tablets in Migraine Prophylaxis: A Double-Blind, Placebo-Controlled Study in Adolescents.

Advanced Bionics

Prism	Precision implantable Stimulator for Migraine Occipital Nerve Stimulation (ONS) for Migraine
-------	--

Alizyme Therapeutics, Ltd.

- ATL1251/038/CL A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Renzapride in Women with Constipation-Predominant Irritable Bowel Syndrome (c-IBS)
- ATL1251/052/CL A Phase III, Multi-Center, Open-Label, Extension Study to Evaluate the Long-Term Safety of Renzapride 4mg Once Daily in Women with Constipation-Predominant Irritable Bowel Syndrome (c-IBS)

Allergan

- 191622-080-00 A Multicenter Study Evaluating the Efficacy and Safety of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Headache Prophylaxis in Migraine Patients with 15 or More Headache Days per 4-Week Period in a 24-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase Followed by a 32-Week Open-Label Extension Phase
- 191622-079-00 A Multicenter Study Evaluating the Efficacy and Safety of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Headache Prophylaxis in Migraine Patients with 15 or More Headache Days per 4-Week Period in a 24-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase Followed by a 32-Week Open-Label Extension Phase.

Alexza

- AMDC-104-201 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Single Dose Efficacy and Safety Study of Staccato® Loxapine for Inhalation in Patients with Migraine Headache
- AMDC-001-202 A Multi-center, Randomized, Double-Blind, Placebo-Controlled, Single Dose, Efficacy and Safety Outpatient Study of Staccato™ Prochlorperazine for Inhalation in Patients with Migraine Headache
- AMDC-001-201 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Staccato Prochlorperazine for Inhalation in Patients with Migraine Headache

BioAlliance

- BA/2005/21/02 A Randomised, Double-Blind, Single-dose, One-Day Early Administration, Multicentre Study comparing the Efficacy and Safety of Acyclovir Lauriad 50 mg muco-adhesive buccal tablet to matching

Placebo, in the Treatment of Herpes Labialis in Immunocompetent Patients" LIP Study (Lauriad Immunocompetent Patients Study)

Capnia

CH-2004-03 Phase II Multi-Center, Randomized, Double-Blind Study to Evaluate The Dose-Related Efficacy and Safety of CAP3 in the Treatment of Acute Migraine (ESCAPE)

Cipher

TRAMCT.02.05 A Double-Blind, Randomized, Placebo-Controlled, Mult-Dose, Phase III, Parallel Group Study of Tramadol ER for the Management of Moderate to Moderately Severe Chronic Pain of Osteoarthritis of the Hip and Knee in Adults.

Eisai Inc.

E2020-A001-213 Extension of E2020-A001-211

E2007-A001-210 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Evaluate the Safety of E2007 in Migraine Prophylaxis

Glaxo Research Institute

TXA107563 A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and tolerability of TREXIMA™ (sumatriptan succinate/naproxen sodium) for a single moderate or severe headache in adults diagnosed with probable migraine without aura (ICHD-II 1.6.1)

COR103561 A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Phosphate Modified Release Formulation (COREG-MR) with Metoprolol Succinate (Toprol-XL) on the Lipid Profile in Normolipidemic, or Mildly Dyslipidemic Hypertensive Patients.

TRX105850 A randomized, double-blind, single migraine attack, placebo-controlled, parallel-group multicenter study to evaluate the efficacy and tolerability of Trexima™ (sumatriptan succinate/ naproxen sodium) tablets vs placebo when administered during the mild pain phase of menstrual migraine in women with dysmenorrhea

TRX103632 A randomized, double-blind, multi-center, placebo-controlled, cross-over study to determine the consistency of response for Trexima™ (sumatriptan 85mg/naproxen sodium 500mg) administered during the mild pain phase for the acute treatment of multiple migraine attacks

SB-767905/014 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Long-Term Safety of Alvimopan 0.5mg Twice Daily for 12 Months for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer Pain

SUM30047 A Randomized Double-Blind, Placebo Controlled, Parallel-Group, Single-Attack Study to Evaluate the Onset of Efficacy Of a New Formulation of Sumatriptan Tablets 50mg and 100mg in the Acute Treatment of Migraine

CXA20008 A Multicenter, Randomized, Double-Blind, Single-Dose Parallel-Group Study to Assess the Safety and Efficacy of the COX2 Inhibitor, GW406381 versus the Placebo and Naproxen Sodium versus Placebo in the Treatment of Migraine

101429 An Evaluation of Satisfaction and Efficacy of the Newly Formulated 100mg Sumatriptan Tablet In A Very Early Intervention Paradigm In Subjects Who Were Previously Dissatisfied with Sumatriptan (Right Formulation, Right Dose, Right Paradigm)

Jazz Pharmaceuticals

06-008 A Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Xyrem® (sodium oxybate) in Subjects with Fibromyalgia

06-010 An Extension study for 06-008

King Pharmaceuticals

K644-07-3001 A Phase 3 Open-Label Study to Assess Subcutaneous Self-Injection with Sumatriptan Succinate using the [Tradename] Auto-injector During a Single Migraine Attack

Map Pharmaceuticals

MAP0004-CL-P201 A Randomized, Double-Blind, Placebo Controlled, Two Part Phase 2 Study of Three Doses of MAO0004 (Tempo™ DHE) in Migraineurs

Merck

078-00 An Observer-blind, Randomized, Parallel-Group Study to Compare the Efficacy of Two Rizatriptan Prescribing Portions for the Treatment of Migraine

MK-0462-081	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Factorial Design Clinical Trial to Study the Efficacy and Safety of MK-0462 / Rizatriptan 10 mg for the Early Treatment of Acute Migraine
011-01	A Multicenter, Double-Blind, Placebo and Active-Controlled, Parallel Group Study to Compare the Efficacy and Safety of Oral MK-0974 with Placebo and Zolmitriptan for the Acute Treatment of Migraine with or without Aura
012-01	A Multicenter, Double-Blind, Active-Controlled, Parallel Group Study to Examine The Safety, Tolerability and Efficacy of Oral MK-0974 for the Long Term Treatment of Acute Migraine with or without Aura
075-00	A Double-Blind, Double-Dummy, Randomized, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Rizatriptan 10mg Co-Administered with Acetaminophen for the Treatment of Acute Migraine
074-00	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Elimination of Migraine-Associated Nausea in Migraine Patients Treated with Rizatriptan Orally Disintegrating Tablet (ODT)
COX523	A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90mg q.d. vs. Diclofenac Sodium 50mg t.i.d. in Patients with Osteoarthritis.
MAX547/065-00	An Open Label Repeat Dose Study of The Safety of Combo Formulation in the Treatment of Multiple Episodes of Acute Migraine over 12 Months
MAX550/066-00	A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Examine the Efficacy of Rizatriptan 10mg Tablet Administered Early During a Migraine Attack While the Pain is Mild

Novartis Pharmaceuticals

COL446HUS136	A randomized, multicenter, double-blind, double-dummy, parallel-group study of acetaminophen or fluvastatin compared to placebo on the transient Post-Dose Symptoms (PDS) following an i.v. infusion of a single dose of zoledronic acid 5mg, in post-menopausal women with low bone mass
CSPA100A2301	A 54-week, open-label, multicenter study to assess the long-term Safety and tolerability of the combination of Aliskiren 300mg/ Amlodipine 10 mg in patients with essential hypertension

LAF237A23104	A multicenter, double-blind, randomized parallel-group study to demonstrate the effect of 24 weeks treatment with vildagliptin 100 mg qd as add-on to metformin 500 mg bid compared to metformin 1000 mg bid in patients with type 2 diabetes inadequately controlled on metformin 500 mg bid monotherapy
CMLF237A2302	A randomized, double-blind, active-controlled, multicenter study to compare the effect of 24 weeks treatment with a fixed combination therapy of vildagliptin and metformin to the individual monotherapy components in drug naïve patients with type 2 diabetes
CSVP100A2301	A 54-week, open-label, multicenter study to assess the long-term safety and tolerability of the combination of aliskiren 300 mg / valsartan 320 mg in patients with essential hypertension.
CLAF237A23119	A multi-center, open-label, active controlled, parallel arm study to compare the efficacy of 12 weeks of treatment with Vildagliptin 100 mg, qd to thiazolidinedione (TZD) as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy in a community-based practice setting
CHTF919N2302	An open label 52-week study to evaluate the safety and efficacy of tegaserod (6 mg b.i.d. and 12 mg o.d.) given orally for the treatment of opioid-induced constipation (OIC) in patients with chronic non-cancer pain
CSPP100A2352	An 8-week, double-blind, randomized, placebo-controlled, multifactorial, parallel-group, multicenter study to evaluate the efficacy and safety of the fixed-dose combinations of aliskiren and HCTZ (150/12.5, 150/25, 300/12.5, 300/25 mg) in patients with essential hypertension
CHTF919E2313	A randomized, double-blind, placebo-controlled, multicenter evaluation of the efficacy and safety of tegaserod 6 mg b.i.d, administered orally for 12 weeks, to patients with chronic constipation, aged 65 years and older
LAF237A2398	A Multicenter, Randomized, Double-Blind, Active Controlled Study to Compare the Effect of 24 Weeks Treatment with Vildagliptin 100 mg qd or Metformin 1500 mg daily in Elderly Drug Naïve Patients with Type 2 Diabetes
CVEA489A2302	An 8-week, multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the combination of valsartan/HCTZ/amlodipine compared to valsartan/HCTZ, valsartan/amlodipine, and HCTZ/amlodipine in patients with moderate to severe hypertension

CSPP100A2344	A 36 week randomized, double-blind, parallel group, multicenter, active-controlled, optional titration study comparing an aliskiren-based regimen to a lisinopril-based regimen in patients \geq 65 years old with systolic essential hypertension
CVAH631D2301	A 6-week, multicenter, randomized, double-blind, parallel-group study to evaluate the combination of valsartan/HCTZ (160/12.5 mg with forced titration to a maximum dose of 320/25 mg) compared to valsartan monotherapy (160 mg with forced titration to 320 mg) as initial therapy in patients with severe hypertension
CVAH631BUS05	A 6-week, multicenter, randomized, parallel-group treatment regimen study to evaluate the efficacy of initial high dose valsartan monotherapy (160mg) or combination therapy (valsartan + hydrochlorothiazide, 160/12.5mg) to conventional low-dose valsartan monotherapy (80mg) in managing patients with hypertension
SPP100A2201	A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Comparing Aliskerin 150mg, 300mg, and 600mg to Placebo and Irbesartan 150mg in Patients with Mild-to-Moderate Hypertension.
CFAM810AUS07	A Six Month Open Label, Randomized Multi-Center Study to Evaluate the Comparative Efficacy and Safety of Oral Famvir (famciclovir) in the Episodic (125mg for 5 days) and Suppressive Treatment (250 mg bid) of Recurrent Genital Herpes
CCOX189A2360	A 13 week, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Trial of 2 Different Dose Regimen of Lumiracoxib (100 mg od and 200 mg od initial Dose for Two Weeks Followed by 100mg od) In Patients With Primary Knee Osteoarthritis Using Celecoxib (200 mg od) as a Comparator
CVAH631C2301	A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Valsartan (320mg) And Hydrochlorothiazide (12.5 And 25mg) Combined And Alone, Valsartan 160 Mg And Valsartan 160 Mg / Hydrochlorothiazide 12.5 Mg In Hypertensive Patients
CHTF919D2301	A 6 Week Randomized Double Blind Placebo-Controlled Multicenter Study, To Assess The Efficacy And Safety Of Tegaserod (6mg BID) And Placebo In Female Patients With Dyspepsia
CLAF237A2303E1	A 28-Week Extension To A Multicenter, Double-Blind Randomized, Parallel-Group Study To Compare The Effect Of 24 Weeks Treatment

With LAF237 (50mg Qd Or Bid) To Placebo As Add-On Therapy In Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy.

- CLAF237A2304E1 A 28-Week Extension To A Multicenter, Double-Blind, Randomized, Parallel-Group Study To Compare The Effect Of 24 Weeks Treatment With LAF237 (50mg Qd Or Bid) To Placebo As Add-On Therapy To Pioglitazone 45 Mg Qd In Patients With Type 2 Diabetes Inadequately Controlled With Thiazolidinedione Monotherapy
- CLAF237A2305E1 A 28-Week Extension To A Multi-Center, Double-Blind Randomized, Parallel-Group Study To Compare The Effect Of 24 Weeks Treatment With LAF237 (50mg Qd Or Bid) To Placebo As Add-On Therapy To Glimepiride In Patients With Type 2 Diabetes Inadequately Controlled With Sulfonylurea Monotherapy
- CFAM810A2403 A Randomized, Multicenter, Double-Blinded, Controlled Study To Compare The Effectiveness Of Single Dose (1500 Mg) Of Famciclovir, One Day (750 Mg Q12) Of Famciclovir And Placebo In Patient-Initiated Episodic Of Recurrent Herpes Labialis
- CFAM810AUS07 A Six Month Open-Label, Randomized, Multi-Center Study To Evaluate The Comparative Efficacy And Safety Of Oral Famvir In The Episodic (125mg Bid For 5 Days) And Suppressive Treatment (250mg Bid) Of Recurrent Genital Herpes
- CSPP100A2307 An Eight Week, Randomized, Double-Blind, Parallel-Group, Multicenter, Dose Escalation Study To Evaluate The Efficacy And Safety Of Aliskiren Administered Alone And In Combination With Ramipril In Patients With Hypertension And Diabetes Mellitus.
- CLAF237A2305 A Multi-Center, Double-Blind, Randomized, Parallel-Group Study To Compare The Effect Of 24 Weeks Treatment With LAF237 (50mg Qd Or Bid) To Placebo As Add-On Therapy To Glimepiride In Patients With Type 2 Diabetes Inadequately Controlled With Sulfonylurea Monotherapy
- CCOX189A2360E1 A 39-Week, Open-Label Extension To CCOX189A2360 A 13-Week Multicenter Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Trial Of 2 Different Dose Regimens Of Lumarcoxib (100mg Od And 200mg Od Initial Dose For Two Weeks Followed By 100 Mg Od) In Patients With Primary Knee Osteoarthritis, Using Celecoxib (200 Mg Od) As A Comparator
- CLAF237A2303 A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 (50 mg qd or

bid) to Placebo as Add-On Therapy in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy

CLAF237A2304

A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 (50 mg qd or bid) to Placebo as Add-On Therapy to Pioglitazone 45 mg qd in Patients with Type 2 Diabetes Inadequately Controlled Thiazolidinedione Monotherapy

CENA13BUS725

A Prospective, Randomized, Parallel-Cohort, Multicenter, 13-Week, Open-Label Comparative Study of the Effects of Exelon® (Rivastigmine Tartrate) 6 to 12 mg/day, Aricept® (Donepezil HCl) 5 to 10 mg/day and Reminyl® (Galantamine Bromide) 16 to 24 mg/day on CSF Cholinesterase Activity in Patients with Mild to Moderate Alzheimer's Disease

Minster Pharmaceuticals

TON/03/07-CLIN

Multi-centre, Parallel Group, Double-Blind, Placebo Controlled, Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache and Open Label Extension

Neuralieve

NL-2006-001

A Phase III Randomized, Double-Blind, Parallel Group, Sham-Controlled Study Evaluating the Efficacy and Safety of Non-invasive, Non-repetitive Transcranial TMS Stimulation (TMS) for the Acute Preemptive Treatment of the Aura Phase of Migraine Headache

Ortho-McNeil

CAPSS-368

Long Term, Open-Label Safety of Oral Almotriptan Malate 12.5mg in the Treatment of Migraine in Adolescents

CAPSS-334

Efficacy of AXERT® (Almotriptan Malate) in the Acute Treatment of Migraine: A Pilot Study of the Potential Impact of Preventive Therapy with TOPAMAX® (Topiramate).

CAPSS-381

Topiramate Intervention to prevent Transformation of EPisoDic Migraine: The Topiramate INTREPID Study

CAPSS-276

A Comparison of the Efficacy and Safety of Topiramate Versus Placebo for the Prophylaxis of Chronic Migraine

CAPSS-277

A Comparison of Topiramate Versus Amitriptyline in Migraine Prophylaxis

CAPSS-316 AXERT Early Migraine Intervention Study (AEGIS): Efficacy and Safety of AXERT (Almotriptan Malate) versus Placebo for the Acute Treatment of Migraine Headache

Pfizer Pharmaceuticals

A3191173 A Double-Blind, Parallel-Group, Randomized, Study of the Efficacy and Safety of “Continuous” Use of Celecoxib vs the “Usual Use” of Celecoxib in the Treatment of Subjects with Chronic Osteoarthritis of the Hip or Knee Who Require an Anti-Inflammatory Medication for Control of Their Pain

A4291023 A Phase 2B Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Evaluating the Efficacy and Safety of PD-0299685 for the Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause

A6061026 [S,S]- Reboxetine Dose-Range Finding Trial: A 16-Week, Randomized, Double-Blind, Placebo And Pregabalin Controlled, Multi-Center Trial Of [S,S]-Reboxetine In Patients With Postherpetic Neuralgia (Phn)

A6061029 An Open-Label Extension Trial Assessing The Safety And Tolerability Of [S,S]-Reboxetine In Patients With Postherpetic Neuralgia (Phn)

A5091031 A Phase 3, Open-Label, Multi-Site, Randomized, Parallel-Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (qd) Compared to Simvastatin for 6 Weeks in Subjects with Hypercholesterolemia

A1601092 An Open-Label Study of Eletriptan for the Acute Treatment of Migraine in Migraine Suffers Who are Dissatisfied with Rizatriptan Therapy.

A1601106 An Observational, Multiple-Attack Study in Migraineurs to Determine the Incidence and Impact of Migraine Relapse and Recurrence Associated with 5HT 1B/1D Agonist (Triptan) Treatment

A0081059 A Six-Month, Double-Blind, Placebo Controlled, Durability of Effect Study of Pregabalin for Pain Associated with Fibromyalgia.

Pozen

LNP-201 A Randomized, Double-Blind, Single-Dose, Placebo-Controlled Evaluation of the Safety and Efficacy of Intravenous Lornoxicam in the Acute Treatment of the Headache of Migraine

MT400-302 A Double-Blind, Multicenter, Randomized, Placebo- Controlled Single Dose Study to Evaluate the Safety and Efficacy of Trexima TM in the Acute Treatment of Migraine Headaches

MT400-303 An Open Label Repeat Dose Study of the Safety of Combo Formulation in the Treatment of Multiple Episodes of Acute Migraine over 12 Months

Schwarz Biosciences

SP906 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety Of 100mg/Day and 300mg/Day Lacosamide for Migraine Prophylaxis

Torrey Pines Pharmaceuticals

NGX424MIG2001 A Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Assess the Safety, Tolerance and Efficacy of a Single Subcutaneous Dose of Tezampanel in Patients with Acute Migraine

Vernalis

VML 251-3MRM02 A Double-Blind, Placebo Controlled Parallel Group Study, with an Open-Label Extension Phase, to Assess the Efficacy, Tolerability And Safety of Oral Frovatriptan in the Prevention of Menstrually- Related Migraine (MRM) Headaches in a "difficult to treat" population

Zogenix

ZX001-0701 A Multi-Center, Open-Label, Single-Dose, Single-Arm Study to Evaluate the Usability of Subcutaneously Administered Sumatriptan Delivered Via the Intraject System in Adult Patients During Acute Migraine Attack